Second call of Implanet’s AGM on 18 May 2021 at 14:00
05 Mai 2021 - 5:45PM
Business Wire
Live presentation of the AGM via web
conference
https://us02web.zoom.us/webinar/register/WN_ykfVpnaURqCe3afIQ-Otsg
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for
PEA-PME equity savings plans), a medical technology company
specializing in vertebral and knee-surgery implants, notifies its
shareholders that its AGM convened on May 5 2021 cannot validly
conduct business due to the quorum required not being reached, and
that a new AGM will be convened to vote on the same agenda on May
18, 2021 at 2:00 pm (CEST/Paris time) behind closed session and
will be broadcast live via web conference.
Shareholders are hereby informed that an Annual General
Meeting on second call will be convened on May 18, 2021 at
2:00pm. Following the same terms of participation as those set
out in the press release published by the Company on 31 March 2021,
the AGM on 18 May will be held behind closed session and will
address the same agenda. A second notice of meeting will be
published on May 7, 2021 in the French official legal announcement
publication BALO and in the JAL.
Moreover, in the absence of the President of the Board, the
Shareholders’ Meeting will be chaired by Mr Ludovic LASTENNET, CEO
and Director in accordance with the by-laws of the Company. The
scrutineers, appointed by Mr Ludovic LASTENNET, pursuant to the
delegation of the Board of Directors of the Company shall be Mr
Régis LE COUEDIC and Mr Denis PASQUET. Mr David DIEUMEGARD, CFO
will perform the duties of secretary.
The participation of Implanet’s shareholders
is decisive in achieving the necessary quorum for this Meeting and
voting on the Company’s resolutions, and notably those pertaining
to the acquisition of Orthopaedic & Spine Development, which
specializes in developing, manufacturing and marketing
implants.
All the logistical elements enabling this Meeting to go ahead
have been implemented to take into account the current public
health situation:
- Online voting is available and should be
prioritized. To this end, the Company informs its shareholders that
the secure VOTACESS voting platform will open on May 7,
2021. Procedures are detailed in the practical guide, available
on the Company’s website. If your financial intermediary (your
bank) subscribes to this VOTACCES platform, you can access
it with your usual username and password via your share management
web interface. Please note that you will no longer be able to log
in to the platform from 3 pm CEST on May 17, 2021. In order
to avoid possible congestion of the VOTACCES website and given the
importance of your vote, the Company recommends that shareholders
do not wait until the day before the General Meeting to provide
their voting instructions.
- Alternatively, you can also vote by post by
sending in the completed and signed paper voting form (subject to
postal service operations), in accordance with the terms indicated
in the notice of the Meeting published in the French official
bulletin of legal notices (‘Bulletin des Annonces Légales
Obligatoire’ – BALO) on May 7, 2021.
The documents pertaining to this General Meeting are available
to shareholders on the Company’s website. Shareholders can email
the Investor Relations team at implanet@newcap.eu with any
questions regarding the voting process.
Votes casted by shareholders by post or online for the first
General Meeting will remain valid, and will be counted for the
second call of the General Meeting.
Upcoming financial events:
- H1 2021 revenue, July 6, 2021 after market - H1 2021
results, September 21, 2021 after market
About Implanet Founded in 2007, Implanet is a medical
technology company that manufactures high-quality implants for
orthopedic surgery. Its activity revolves around two product
ranges, the latest generation JAZZ® implant, designed to improve
the treatment of spinal pathologies requiring vertebral fusion
surgery, and the MADISON implant designed for first-line prosthetic
knee surgery. Implanet’s tried-and-tested orthopedic platform is
based on product traceability. Protected by four families of
international patents, JAZZ® and MADISON have obtained 510(k)
regulatory clearance from the Food and Drug Administration (FDA) in
the United States, the CE mark as well as the ANVISA authorization
in Brazil. Implanet employs 29 staff and recorded 2020 sales of
€6.0 million. For further information, please visit
www.implanet.com. Based near Bordeaux in France, Implanet
established a US subsidiary in Boston in 2013. Implanet is listed
on Euronext™ Growth market in Paris.
The Company would like to remind that the table for monitoring
the equity line (OCA, OCAPI, BSA) and the number of shares
outstanding, is available on its website:
http://www.implanet-invest.com/suivi-des-actions-80
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210505005787/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tel.: +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Mathilde Bohin Nicolas Fossiez
Tel.: +33 (0)1 44 71 94 94 Implanet@newcap.eu
NewCap Media Relations Nicolas Merigeau Tel.: +33 (0)1 44
71 94 94 Implanet@newcap.eu
Implanet (EU:ALIMP)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Implanet (EU:ALIMP)
Historical Stock Chart
Von Apr 2023 bis Apr 2024